{"id":70664,"date":"2026-05-12T08:56:17","date_gmt":"2026-05-12T08:56:17","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70664"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mots-c","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/mots-c\/","title":{"rendered":"MOTS-c"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Risposta rapida \u2014 Cos'\u00e8 MOTS-c?<\/h3>\n<p style=\"margin: 0;\"><strong>MOTS-c<\/strong> (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16-amino-acid mitochondrially-encoded signaling peptide first identified in 2015. In published preclinical studies it acts as an exercise-mimetic and metabolic regulator by activating the AMPK pathway, restoring insulin sensitivity, and modulating nuclear gene expression in response to mitochondrial stress. Supplied in 10\u00a0mg to 40\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1627580-64-6<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formula Molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2174.62 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR, 16 amminoacidi; codificato all'interno del gene mitocondriale 12S rRNA)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvere liofilizzata (da bianca a biancastra)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificato con HPLC, COA disponibile su richiesta)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138 \u00b0C (frigorifero) per lo stock di lavoro; \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Ricostituito: 2\u20138 \u00b0C, utilizzare entro ~30 giorni. Proteggere dalla luce. Non congelare e scongelare la soluzione ricostituita.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Acqua batteriostatica (consigliata) o acqua sterile per finestre d'uso pi\u00f9 brevi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 il MOTS-c?<\/h2>\n<p><strong>MOTS-c<\/strong> (Mitochondrial Open Reading frame of the Twelve S rRNA-c) \u00e8 un peptide di 16 amminoacidi identificato per la prima volta da Lee et al. in <em>Cell Metabolism<\/em> (2015) as a member of the newly recognised class of mitochondrially-derived peptides (MDPs). Unlike every other peptide in the studies catalog \u2014 which are encoded by nuclear DNA and synthesised in the cytoplasm \u2014 MOTS-c is encoded within the mitochondrial 12S rRNA gene and translated by mitochondrial ribosomes. This unusual biological origin makes it a direct intracellular signal of mitochondrial state, and the most-cited member of a peptide class that includes humanin and the SHLP family. The peptide sequence is MRWQEMGYIFYPRKLR, molecular weight approximately 2,175\u00a0Da, empirical formula C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub>. Il MOTS-c endogeno si sposta dai mitocondri al nucleo sotto stress metabolico e ossidativo, dove regola un programma genico del ciclo dei folati\/metabolismo della metionina \u2014 un meccanismo senza paralleli tra i peptidi codificati dal nucleo. Il MOTS-c viene fornito come polvere liofilizzata ad alta purezza per ricostituzione con acqua batteriostatica ed \u00e8 <strong>for clinical studies use only<\/strong>. For related metabolic and longevity peptides, see our full <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">catalogo peptidi<\/a>. <\/p>\n<h2>Meccanismo d'azione \u2014 AMPK, metabolismo del glucosio e traslocazione nucleare<\/h2>\n<p>Ci\u00f2 che differenzia il MOTS-c dai peptidi metabolici pi\u00f9 vecchi \u00e8 il suo <strong>meccanismo d'azione tri-modale<\/strong> that spans the mitochondrion, the cytoplasm, and the nucleus \u2014 each contributing to the observed metabolic phenotype in published studies:<\/p>\n<ul>\n<li><strong>attivazione della via AMPK<\/strong> \u2014 MOTS-c attiva la proteina chinasi attivata da AMP (AMPK), il principale sensore energetico cellulare, aumentando il rapporto AMP:ATP intracellulare e attraverso un meccanismo dipendente dal ciclo dei folati. L'attivazione di AMPK sposta il metabolismo cellulare verso il catabolismo: aumento dell'assorbimento del glucosio tramite traslocazione di GLUT4, ossidazione degli acidi grassi, biogenesi mitocondriale attraverso PGC-1\u03b1 e autofagia. Questa \u00e8 la stessa via bersagliata dalla metformina e dall'esercizio fisico, che ha valso a MOTS-c la descrizione di \u201cpeptide mimetico dell'esercizio\u201d nella letteratura pubblicata.<\/li>\n<li><strong>sensibilit\u00e0 all'insulina e smaltimento del glucosio<\/strong> \u2014 In high-fat-diet rodent models, MOTS-c administration restores insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. The effect is independent of body-weight change in some studies designs, suggesting a direct insulin-sensitising mechanism rather than secondary to weight loss. MOTS-c-treated obese mice show normalised oral glucose tolerance and improved euglycaemic-clamp parameters in published studies.<\/li>\n<li><strong>traslocazione nucleare ed espressione genica adattativa<\/strong> \u2014 In condizioni di stress metabolico o ossidativo, MOTS-c si trasloca dai mitocondri al nucleo dove co-regola un programma trascrizionale incentrato sulla risposta antiossidante (NRF2), il ciclo folato-metionina e i geni metabolici adattativi. Questa segnalazione retrograda mitocondriale-nucleare \u00e8 uno dei primi esempi a livello peptidico di comunicazione intracellulare tra compartimenti ed \u00e8 alla base degli effetti pi\u00f9 ampi di MOTS-c oltre alla diretta attivazione di AMPK.<\/li>\n<\/ul>\n<p>The biological appeal of MOTS-c in metabolic support is the convergence of these three mechanisms onto pathways already known to mediate the benefits of exercise and caloric restriction. Because endogenous MOTS-c declines markedly with age in human serum (~50% reduction across adult lifespan in published cohorts), the peptide has become a frequent target in aging and longevity studies as well as in metabolic syndrome. <\/p>\n<h2>Published Evidence<\/h2>\n<p>MOTS-c is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Metabolic syndrome and obesity studies<\/strong> \u2014 insulin sensitivity, glucose tolerance, body composition in high-fat-diet rodent models; benchmark peptide for AMPK-axis intervention studies (Lee et al., Cell Metabolism 2015; Reynolds et al., Front Physiol 2021)<\/li>\n<li><strong>modelli preclinici di diabete di tipo 2<\/strong> \u2014 modelli di diabete db\/db, ZDF e indotti da streptozotocina; effetti sulla sensibilit\u00e0 all'insulina epatica, funzione delle cellule beta e surrogati di HbA1c<\/li>\n<li><strong>capacit\u00e0 di esercizio e biogenesi mitocondriale<\/strong> \u2014 resistenza al tapis roulant, VO<sub>2<\/sub>max surrogates, PGC-1\u03b1 expression, mitochondrial DNA copy number in skeletal muscle studies<\/li>\n<li><strong>Aging and longevity studies<\/strong> \u2014 lifespan extension models, age-related insulin resistance, sarcopenia; MOTS-c serum levels decline with age, making it a candidate replacement peptide in geroscience studies<\/li>\n<li><strong>Protezione cardiovascolare e renale<\/strong> \u2014 ischaemia-reperfusion injury, oxidative stress markers, mitochondrial dysfunction in cardiac and renal tissue study models<\/li>\n<li><strong>Bone health studies<\/strong> \u2014 differenziazione degli osteoblasti, densit\u00e0 minerale ossea, modelli di osteoporosi legati all'et\u00e0<\/li>\n<li><strong>Comparative mitochondrial peptide studies<\/strong> \u2014 confronto con altri peptidi mirati ai mitocondri come <a href=\"https:\/\/medsbase.com\/it\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a>. Consulta la sezione di confronto qui sotto per un confronto metodologico affiancato.<\/li>\n<\/ul>\n<p>Per un contesto pi\u00f9 ampio su dove si colloca MOTS-c nel panorama dei peptidi metabolici e della longevit\u00e0, vedi <a href=\"https:\/\/medsbase.com\/it\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> come il peptide mitocondriale canonico mirato alla cardiolipina, <a href=\"https:\/\/medsbase.com\/it\/epitalon\/\">Epitalon<\/a> for telomere\/longevity studies, and <a href=\"https:\/\/medsbase.com\/it\/nad\/\">NAD+<\/a> for NAD-axis metabolic support. Browse the full <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">catalogo peptidi<\/a> per composti correlati. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks MOTS-c in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosaggio per Flaconcino<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, short-cycle protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Flaconcino di media gamma per volumi ridotti di ricostituzione per dose<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle protocols, longevity studies, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials yield greater per-vial dose flexibility and lower per-mg cost; the trade-off is that reconstituted solution must be used within 30 days, so multi-month protocols benefit from larger vials only when the per-week dose is correspondingly high. <\/p>\n<h2>Confronto \u2014 MOTS-c vs SS-31 (Elamipretide)<\/h2>\n<p>MOTS-c e <a href=\"https:\/\/medsbase.com\/it\/ss-31-elamipretide\/\">SS-31<\/a> are the two most-cited mitochondrially-targeted peptides in current studies. They are mechanistically distinct and complementary, not redundant: MOTS-c is a signalling peptide that activates AMPK and nuclear-encoded adaptive programmes, while SS-31 is a structural peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. Users often pair them in mitochondrial-dysfunction models for this reason. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">MOTS-c<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">SS-31 (Elamipretide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Lunghezza<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 aminoacidi<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4 aminoacidi (tetrapeptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origine<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">DNA mitocondriale codificato (gene 12S rRNA)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Peptide sintetico Szeto-Schiller<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meccanismo primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Attivazione AMPK, espressione genica nucleare<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Legame cardiolipina, stabilizzazione ETC<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Bersaglio cellulare<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mitocondrio \u2192 citoplasma \u2192 nucleo<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Solo membrana mitocondriale interna<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosaggio tipico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5\u201315 mg, 1\u20133 volte a settimana<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u20135 mg, giornalmente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sensibilit\u00e0 insulinica, capacit\u00e0 fisica, invecchiamento<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ischemia cardiaca, disfunzione mitocondriale renale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Stacking<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frequently co-administered with SS-31 in mitochondrial studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frequentemente co-somministrato con MOTS-c<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides act on different layers of mitochondrial biology \u2014 MOTS-c regulates metabolic transcription, SS-31 stabilises membrane architecture \u2014 so they address non-overlapping studies questions. For metabolic\/insulin sensitivity, MOTS-c is the default first choice. For cardiac, renal, or ischaemia-reperfusion mitochondrial protection, SS-31 is the canonical comparator. <\/p>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare i flaconcini liofilizzati refrigerati a 2\u20138 \u00b0C nella confezione originale per lo stock di lavoro a breve termine. Per lo stoccaggio a lungo termine non aperto, congelare a \u221220 \u00b0C. Il MOTS-c liofilizzato \u00e8 stabile in refrigerazione fino a 24 mesi e a \u221220 \u00b0C fino a 36 mesi. Evitare cicli di congelamento-scongelamento sulla polvere liofilizzata. <strong>Procedura di ricostituzione:<\/strong> iniettare acqua batteriostatica lungo la parete laterale del flaconcino del peptide (non direttamente sulla torta liofilizzata). Per un flaconcino da 10 mg, 2,0 mL di acqua batteriostatica producono una concentrazione di lavoro di 5 mg\/mL \u2014 10 tacche su una siringa per insulina U-100 equivalgono a 500 mcg. Agitare delicatamente \u2014 non <strong>not<\/strong> scuotere \u2014 e attendere 2\u20135 minuti per la completa dissoluzione. Una soluzione ricostituita correttamente dovrebbe essere chiara e incolore. <strong>Dopo la ricostituzione:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because MOTS-c is typically dosed 1\u20133 times weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20133 weeks of dosing depending on the target dose and frequency. <\/p>\n<h2 id=\"faqs\">Domande frequenti<\/h2>\n<h3>What is MOTS-c used for in studies?<\/h3>\n<p>MOTS-c is used in studies investigating insulin sensitivity, type 2 diabetes models, exercise capacity, mitochondrial biogenesis, aging and longevity, cardiovascular ischaemia-reperfusion injury, renal mitochondrial dysfunction, and bone health. It is the most-cited mitochondrially-encoded signalling peptide in the published literature and serves as a benchmark for AMPK-axis interventions. MOTS-c is <strong>not<\/strong> FDA-approved and is supplied here strictly for clinical studies use only. <\/p>\n<h3>In cosa differisce il MOTS-c dallo SS-31 (Elamipretide)?<\/h3>\n<p>MOTS-c is a 16-amino-acid signalling peptide encoded by mitochondrial DNA that activates AMPK and regulates nuclear gene expression. SS-31 is a 4-amino-acid synthetic Szeto-Schiller peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. The two address different layers of mitochondrial biology \u2014 MOTS-c at the metabolic-transcription level, SS-31 at the membrane-architecture level \u2014 and are frequently co-administered in mitochondrial-dysfunction studies. <\/p>\n<h3>What is the typical MOTS-c dose?<\/h3>\n<p>I protocolli preclinici pubblicati utilizzano tipicamente 5\u201315 mg per somministrazione in modelli roditori, somministrati 1\u20133 volte a settimana per cicli di 4\u201312 settimane. Un flaconcino da 10 mg ricostituito con 2,0 mL di acqua batteriostatica produce 5 mg\/mL \u2014 10 tacche su una siringa U-100 equivalgono a 500 mcg. <\/p>\n<h3>Il MOTS-c \u00e8 approvato dalla FDA?<\/h3>\n<p>No. MOTS-c is not approved by the FDA, EMA, MHRA, or any other regulator for human therapeutic use. <\/p>\n<h3>Come deve essere conservato il MOTS-c?<\/h3>\n<p>Flaconcini liofilizzati: refrigerati a 2-8 \u00b0C per scorte di lavoro a breve termine, o -20 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Soluzione ricostituita: refrigerata a 2-8 \u00b0C, utilizzare entro 30 giorni. Non congelare la soluzione ricostituita - i cicli di congelamento-scongelamento degradano il peptide. Proteggere sempre dalla luce diretta. <\/p>\n<h3>Come si ricostituisce il MOTS-c?<\/h3>\n<p>Seguire la procedura di ricostituzione sopra indicata. Aggiungere acqua batteriostatica lungo la parete laterale del flaconcino (non direttamente sulla polvere liofilizzata), agitare delicatamente e attendere 2-5 minuti per la completa dissoluzione. Non <strong>not<\/strong> agitare il flaconcino. Una soluzione correttamente ricostituita \u00e8 limpida e incolore. Per un flaconcino da 10 mg + 2,0 mL di diluente, la concentrazione di lavoro \u00e8 di 5 mg\/mL. <\/p>\n<h3>Quali dosaggi sono disponibili su MedsBase?<\/h3>\n<p>MedsBase carries MOTS-c in 10\u00a0mg, 20\u00a0mg, and 40\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Perch\u00e9 il MOTS-c \u00e8 chiamato peptide \u201cmimetico dell'esercizio\u201d?<\/h3>\n<p>The term derives from MOTS-c&#8217;s activation of AMPK and downstream effects on glucose uptake, fatty acid oxidation, and mitochondrial biogenesis \u2014 the same intracellular pathway responsible for many of the metabolic adaptations to exercise. In published studies, MOTS-c administration replicates several phenotypes of exercise training in sedentary animals: improved insulin sensitivity, increased treadmill endurance, and elevated PGC-1\u03b1 expression in skeletal muscle. The metaphor is widely used in geroscience and metabolic-syndrome literature. <\/p>\n<h3>Can MOTS-c and SS-31 be stacked in studies?<\/h3>\n<p>Yes. MOTS-c and SS-31 act on different layers of mitochondrial biology and are frequently co-administered in preclinical mitochondrial-dysfunction studies. MOTS-c regulates metabolic transcription via AMPK; SS-31 stabilises the inner-membrane lipid environment. Their mechanisms are complementary rather than overlapping, which makes the combination useful in study models of multi-axis mitochondrial decline. <\/p>\n<h3>Does MOTS-c cause side reported effects?<\/h3>\n<p>Published preclinical studies has reported a notably clean safety profile at typical doses in rodent models, with no consistent off-target signals and good tolerability across 4\u201312 week dosing cycles. MOTS-c is structurally an endogenous human peptide, which reduces the risk of antibody-mediated reactions seen with engineered analogs. Long-term human safety data are not available because human trials are still in early stages. <\/p>\n<h3>Qual \u00e8 l'emivita del MOTS-c?<\/h3>\n<p>In preclinical studies, MOTS-c has an estimated plasma half-life of approximately 3\u20134 hours following subcutaneous administration. The relatively short systemic half-life is offset by intracellular accumulation and the peptide&#8217;s role as an intracellular signalling molecule rather than a circulating hormone \u2014 effects persist beyond the plasma clearance window in study models. <\/p>\n<h3>Perch\u00e9 il MOTS-c endogeno diminuisce con l'et\u00e0?<\/h3>\n<p>Published cohort data show roughly a 50% decline in human serum MOTS-c levels between young and aged adults. The mechanism is not fully understood but is thought to relate to age-associated mitochondrial DNA mutations, declining mitochondrial transcription, and reduced biosynthesis of mitochondrially-encoded peptides in general. The age-related decline is one reason MOTS-c has attracted strong interest in longevity and geroscience studies. <\/p>\n<h3>How long does MOTS-c take to show effects in preclinical studies?<\/h3>\n<p>Gli effetti acuti sulla fosforilazione dell'AMPK e sull'assorbimento del glucosio sono rilevabili entro poche ore dalla somministrazione. Gli effetti sulla sensibilit\u00e0 all'insulina e sulla composizione corporea nei modelli roditori con dieta ricca di grassi diventano tipicamente statisticamente significativi dopo 2-4 settimane di somministrazione regolare. I miglioramenti della capacit\u00e0 di esercizio (resistenza al tapis roulant, surrogati del VO<sub>2<\/sub>max surrogates) accrue over 4\u20138 weeks of continuous dosing. <\/p>\n<h3>Posso ordinare MOTS-c per la spedizione internazionale?<\/h3>\n<p>S\u00ec. MedsBase spedisce MOTS-c in tutto il mondo dalla nostra rete dedicata di spedizione di peptidi. Gli ordini contenenti solo peptidi si qualificano per il nostro servizio di spedizione di peptidi autonomo. Tutti gli ordini vengono spediti in imballaggi a temperatura controllata con tracciamento completo e sono coperti dal nostro <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\">Politica di Garanzia di Rispedizione<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Mitochondrial, and Longevity Studies<\/h2>\n<ul>\n<li><a href=\"\/it\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 Tetrapeptide mitocondriale legante la cardiolipina \u2014 stabilizzatore canonico della membrana interna<\/li>\n<li><a href=\"\/it\/nad\/\"><strong>NAD+<\/strong><\/a> \u2014 Nicotinamide adenine dinucleotide \u2014 sirtuin\/longevity-axis metabolic support<\/li>\n<li><a href=\"\/it\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 telomerase activation and longevity studies<\/li>\n<li><a href=\"\/it\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Long-acting GLP-1 agonist \u2014 glycaemic and body-weight studies<\/li>\n<li><a href=\"\/it\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Approfondimenti<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Confronta i peptidi mirati ai mitocondri<\/strong><\/p>\n<p style=\"margin: 0;\">Esplora l'ampia gamma <a href=\"https:\/\/medsbase.com\/it\/peptides\/\"><strong>catalogo peptidi<\/strong><\/a> di peptidi mitocondriali e metabolici, inclusi <a href=\"https:\/\/medsbase.com\/it\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-targeted membrane studies, <a href=\"https:\/\/medsbase.com\/it\/nad\/\">NAD+<\/a> for sirtuin-axis longevity studies, and <a href=\"https:\/\/medsbase.com\/it\/epitalon\/\">Epitalon<\/a> for telomere-axis longevity studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Peptide di segnalazione codificato dai mitocondri<br \/>\n\u2705 Attiva il percorso metabolico AMPK<br \/>\n\u2705 Migliora la sensibilit\u00e0 all'insulina<br \/>\n\u2705 Mima l'esercizio fisico nei modelli preclinici<br \/>\n\u2705 Longevity &amp; geroscience compound<\/p>\n<p><strong>MOTS-c<\/strong> contiene composto peptidico sintetico.<\/p>","protected":false},"featured_media":70967,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6272,5441],"class_list":["post-70664","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mots-c","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/70664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=70664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/70967"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=70664"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=70664"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=70664"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=70664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}